it’s all about the increased costs of bigger trials. Looking back at the quarterly trial costs is one thing. I am sure the BOD have a cash flow forecast that takes into account the rebates / options and all costs
If the company says it’s fully funded then who are we to challenge, given that we don’t have the details
That bring said, I do think that there will be a boost to the coffers in the form of a deal with Big Pharm in one form or another, hopefully by the end of quarter 2 2021.
Ann: Appendix 4C - quarterly, page-38
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
-0.004(6.67%) |
Mkt cap ! $411.5M | |||
| Open | High | Low | Value | Volume |
| 5.9¢ | 5.9¢ | 5.5¢ | $1.481M | 26.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 400000 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 685507 | 4 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |